At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 93 enrolled
Drug / intervention
Veru-944 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind, Placebo Controlled, Dose Finding Phase 2 Study Comparing Oral Daily Dosing of VERU-944 to Ameliorate the Vasomotor Symptoms Resulting From ADT in Men With Advanced Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Veru-944 and Placebo for Prostate Cancer Metastatic. Completed, enrolled 93 participants across 24 sites.
Detailed Summary
Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer Metastatic
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartSep 2018
Primary CompletionApr 2020
Study CompletionOct 2020
TodayJul 2026
First PostedAug 24, 2018
Enrollment StartSep 14, 2018
Primary CompletionApr 30, 2020
Study CompletionOct 15, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.9 years ago
Interventions
Veru-944drug
Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
Placebodrug
Placebo